Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $6.6678 per share on October 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 15, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $6.6678 per share, with individual trades ranging from $6.50 to $6.74.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• Following the transaction, Borgeson directly owns 7,089,007 shares of Recursion Pharmaceuticals' Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares by a company director under a pre-arranged trading plan.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about trading on non-public information. It is important to consider the overall context of insider transactions, including the company's performance, industry trends, and the insider's reasons for selling.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.
• However, the existence of a 10b5-1 trading plan mitigates concerns about insider trading, as the plan was established well in advance of the transaction.

Key Dates